Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025

Upregulation of SLC25A1 by MAZ reprograms fatty acid synthesis and fuels LUAD malignancy.

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiaomeng LiJLJing Li

Discussion

Loading...

Member takes

Overview

Investigation reveals that MAZ regulates SLC25A1 expression and enhances fatty acid synthesis in LUAD, suggesting new therapeutic strategies.

Key Points

  • Upregulation of SLC25A1 in LUAD correlates with poor prognosis and promotes cell proliferation.
  • In this study, MAZ was shown to positively regulate SLC25A1, boosting fatty acid synthesis in LUAD cells.
  • In vivo studies demonstrated that MAZ accelerates the malignant progression of LUAD via SLC25A1 regulation.
  • The findings suggest MAZ and SLC25A1 as potential targets for therapeutic strategies in LUAD patients.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68dd89e6fe798ba2fc497f82https://doi.org/10.4149/gpb_2025036
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SLC25A39 overexpression exacerbates lung adenocarcinoma progression and is negatively regulated by AFG3L22025 · 1 citations
  2. 2The role of SLC2A1 in lung adenocarcinoma: From tumorigenesis to patient survival2025
  3. 3ZDHHC5 as a central regulator in a palmitoylation-associated prognostic model for lung adenocarcinoma: insights from pan-cancer and experimental analyses2025
  4. 4APOA1 as a Potential Therapeutic Target and Novel Biomarker in Lung Adenocarcinoma2025
  5. 5MRPL15 as a Key Gene in the Malignant Proliferation of LUAD2025